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Abstract: The E2F transcription factor family is traditionally associated with cell cycle 
control.  However,  recent  data  has  shown  that  activating  E2Fs  (E2F1-3a)  are  potent 
activators  of  apoptosis.  In  contrast,  the  recently  cloned  inhibitory  E2Fs  (E2F7  and  8) 
appear to antagonize E2F-induced cell death. In this review we will discuss (i) the potential 
role of E2Fs in UV-induced cell death and (ii) the implications of this to the development 
of UV-induced cutaneous malignancies. 
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1. What is UV? 
Life on earth is dependent upon UV radiation as an energy source. Ironically, whilst humans are 
dependent upon UV radiation for their existence, UV radiation is a common and potent carcinogen for 
people of Caucasian descent [1].  
Ultraviolet (beyond violet) refers to wavelengths shorter than visible violet light and longer than  
X-rays [2]. The UV radiation spectrum is grouped into three categories based on wavelength. UVC 
(200–280  nm)  is  the  most  potent  carcinogenic  band  of  UV  but  poses  little  threat  to  terrestrial 
organisms since it is almost completely absorbed by the earth’s atmosphere. Only 10% of incident 
UVB (280–320 nm) radiation penetrates the atmosphere. The vast majority of incident UV (greater 
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than 90%) radiation comes from UVA (320–400 nm). Although UVA radiation predominates at sea 
level, UVB has the highest energy and is 1,000 times more erythematogenic than UVA [2]. Thus, the 
carcinogenic potential of the UV spectrum reaching the earth’s surface is a composite of a small 
amount of high energy UVB and a large amount of low energy UVA. Combined, UVA and UVB 
radiation  damage  DNA,  disrupt  pro-apoptotic  signaling  pathways  and  suppress  immune  responses 
ultimately contributing to the carcinogenic action of sunlight [3]. Despite the more potent carcinogenic 
activity of UVB it is only capable of penetrating the more superficial epidermal layers whereas UVA 
can penetrate deeper into the dermis [2].  
2. Mutagenic Effects of UV Radiation 
UV light is a physical mutagen and can ionize molecules resulting in the conversion of absorbed 
light energy into biochemical reactions. DNA is one of the major molecules capable of absorbing UV 
radiation.  Absorbed  UV  radiation  causes  DNA  damage  via  the  formation  of  DNA  lesions  often 
referred to as photolesions [4]. DNA damage caused by UVA and UVB can be direct or indirect. 
Direct absorption of UVB by DNA results in the formation of photolesions such as cyclo-butane-
pyrimidine dimers (CPDs) and pyrimidine (6–4) pyrimidone dimers [5] (Table 1). If these pyrimidine 
dimers  are  not  repaired  by  DNA  repair  mechanisms,  it  may  result  in  heritable  base  transitions. 
Formation of these, C→T single or CC→TT double, transitions at dipyrimidine sites is mutagenic and 
the nature and the presence of these lesions are frequently referred to as the UVB signature [6]. On the 
other  hand,  UVA  is  not  absorbed  by  DNA  and  causes  DNA  damage  via  an  indirect  mechanism 
involving the generation of reactive oxygen species (ROS) generated by UVA-mediated activation of 
photosensitizers  (e.g.,  riboflavin,  porphyrins,  quinines)  resulting  in  the  accumulation  of  CPDs  [7]. 
UVB may also cause the accumulation of ROS and hence can also facilitate indirect DNA damage, 
albeit to a lesser extent than observed with UVA [8] (Table 1).  
Table 1. Summary of mutagenic effects of UVA and UVB. 
  UVA  UVB 
Wavelength (nm)  320–400  280–320 
Chromophores  Photosensitizers  DNA 
Site of damage  ROS  Pyrimidine dimers (CDP) 6–4 photoproducts 
Mechanism  Indirect  Direct 
3. Sunburn Cells (UV-Induced Cell Death) 
Following  UV  exposure  keratinocytes  will  follow  one  of  two  fates.  If  the  damage  to  DNA  is 
perceived to be reparable, the keratinocytes will undergo a reversible growth arrest accompanied by 
the mobilisation and activation of the nucleotide excision repair system (NER). This leads to the repair 
of damaged DNA (mutations/DNA lesions) and is facilitated by secreted cytokines, IL12 and IL18, 
which  can  restore  immune  responses  and  prevent  from  UV-induced  immunosuppression  [9–11]. 
Alternatively, if the DNA damage is perceived to be too great and the cells lack the capacity to repair 
the damage then the cells will be induced to apoptose [12,13]. Apoptosis, or programmed cell death, is 
a mechanism that prevents cells from passing on mutated DNA to their progeny. Thus, the apoptotic Int. J. Mol. Sci. 2011, 12                       
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machinery  provides  a  means  by  which  mutated,  potentially  premalignant  cells  are  able  to  be  
eliminated  [14].  UV-induced  apoptosis  results  in  the  formation  of  so-called  “sunburn  cells”  or 
apoptotic keratinocytes. Sunburn cells are easily identified by the presence of photo lesions, pyknotic 
nuclei  and  cytoplasmic  shrinkage  characteristic  of  apoptotic  cells  [15].  UV-induced  apoptotic 
responses  are  mediated  via  extrinsic/death  receptor  signaling  and  intrinsic/mitochondrial  death 
pathways [11,16]. The extrinsic death pathway is initiated by the binding of membrane death receptors 
TNF-R1, CD95, TRAIL-R1 and TRAIL-R2 to their cognate ligands, TNF-α, CD95L/FASL or TRAIL 
(TNF-related  apoptosis-inducing  ligand).  UV  can  also  activate  CD95  death  receptor  signaling 
pathways independent of its natural ligand CD95L [17]. The subsequent formation of a death-inducing 
signaling complex (DISC) is characteristic of death receptor-mediated apoptosis in response to UV 
radiation [18,19]. Activation of death receptor signaling ultimately activates the initiator pro-caspases-
8/-10 leading to the eventual activation of downstream effector procaspases-3,-6,-7 [12]. Activation of 
the intrinsic apoptotic pathway is stimulated by the release of cytochrome c from outer mitochondrial 
membrane [20]. Activation of the intrinsic apoptotic pathway is controlled by the balance between  
pro-apoptotic  (Bax,  Bak,  Bad,  Bid,  Bim)  and  anti-apoptotic  (Bcl-2,  Bcl-Xl,  Mcl-Xl)  Bcl-2  family 
proteins. When pro-apoptotic stimuli predominate, it leads to the permeabilisation of the mitochondrial 
outer membrane potential leading to cytochrome C release and eventual procaspase-9 activation [21,22] 
(Figure 1).  
Figure  1.  UV-mediated keratinocyte apoptosis can be initiated by extrinsic or intrinsic 
pathways. Extrinsic pathways include death receptor activation via death ligand binding, 
DISC formation, activation of pro-caspases and activation of effector caspase-3 leading to 
apoptosis. Activation of intrinsic pathways induces cytochrome c release from mitochondria 
and activation of pro-apoptotic Bcl-2 proteins and inhibition of anti-apoptotic Bcl-2 proteins, 
activation of pro-caspase-9 and activation of effector caspase-3 leading to apoptosis. 
 
4. Role of UV in Skin Carcinogenesis 
Skin  cancers  are  frequently  divided  into  melanoma  and  non-melanoma  skin  cancers  (NMSC). 
Regardless of classification, the main contributory factor in the development of cutaneous malignancies, 
in humans, is UV exposure [23]. Melanoma is a common and aggressive tumour type derived from 
melanocytes.  The  major  forms  of  non-melanoma  skin  cancer  are  basal  cell  carcinoma  (BCC)  and 
squamous cell carcinoma (SCC) [24]. In a recent study, Trakatelli et al. [25] showed that NMSC had Int. J. Mol. Sci. 2011, 12                       
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significantly increased in incidence in Caucasians in the last decade. NMSC skin cancers are the most 
common malignancy in Caucasians and their incidence reflects the potent carcinogenic activity of UV 
radiation  [26].  There  are  a  number  of  reviews  on  the  molecular  mechanisms  associated  with  
UV-induced skin cancer and in particular we refer the reader to other articles within this issue of the 
journal. Of relevance to the current review are reports that UV-induced SCC formation is associated 
with dysregulation of the control of proliferation, differentiation and apoptosis [27–31]. Amongst these 
known changes it is notable that disruption of the Rb/E2F axis is over-represented. In particular, there 
is  considerable  data  relating  to  the  expression,  activity  and  role  of  dysregulated  E2F1  in  SCC 
formation [26,32–35]. For example, disruption of the Rb/E2F axis is common in almost all human 
cancers including SCC [36]. Loss of function mutations of p53, Rb, or upstream regulators of the 
Rb/E2F axis such as INK4A (p16) are frequently associated with SCC and may result from mutation, 
deletion  or  promoter  hypermethylation  [37–39].  Moreover,  SCCs  are  frequently  associated  with 
amplification/activation of mitogenic pathways controlled by cyclin D1, cdk4 or EGFR [31,40]. All 
these events are known to contribute to the dysregulation of proliferation and differentiation [31,40,41]. 
In addition, dysregulation of enzymes regulating oxidative stress such as GPX2 have also been shown 
to contribute casually to UV-induced SCC formation [25]. Dysregulation of antioxidant enzymes is 
known to disturb the apoptotic axis. Indeed, apoptotic regulators related to sensitivity and response to 
UV-induced damage are invariably targeted during keratinocyte transformation [13]. Consequently, 
the  major  safeguard  that  keratinocytes  use  to  protect  themselves  against  UV-induced  mutations, 
namely sunburn cell formation, is compromised in keratinocytes following exposure to carcinogenic 
doses of UV [41]. However, the exact mechanisms by which UV-induced mutational damage contributes 
to the biological events controlling keratinocyte transformation and SCC progression remain unclear.  
5. The E2F Family 
The  squamous  differentiation  program  of  the  epidermis  involves  co-ordinate  regulation  of 
proliferation, differentiation and apoptosis. The barrier functions of the epidermis depend upon the 
integrity of this program and its ability to respond to environmental insults such as UV radiation [7,42]. 
The process of squamous differentiation is a tightly regulated process in which transcription factors 
control  the  differentiation  program  and  its  barrier  functions  [36].  Thus,  it  is  not  surprising  that 
disruption to transcriptional control is a frequent target in oncogenesis [43]. Many transcription factors 
have been implicated in the control of squamous differentiation and carcinogenesis. However, the E2F 
family  of  transcription  factors  have  emerged  as  pleiotropic  regulators,  directly  controlling  (i)  cell 
proliferation,  (ii)  apoptosis,  (iii)  differentiation,  (iv)  DNA-damage  response  and  DNA  repair,  
(v)  development,  (vi)  senescence  and  (vii)  autophagy  [28,29,44–49].  Moreover,  E2Fs  are  also 
indirectly involved in modulating the activity of important cellular signaling pathways such as MAPK, 
p38 and PI3-K/AKT through transcriptional regulation of upstream pathway components [50,51]. 
E2F  was  first  discovered  as  a  cellular  factor  required  for  the  activation  of  the  E2  viral  
promoter  [29,52].  This  factor  was  later  cloned  and  named  E2F1  [43].  However,  it  was  quickly 
recognised that E2F1 was just one member of, what is now, a family of 8 members, E2Fs 1–8, coding 
for 10 different E2F forms [53]. The role of the E2Fs is complex. Individual E2F family members can 
be involved in multiple cellular activities. For example, E2F1 is directly involved in the G1/S transition Int. J. Mol. Sci. 2011, 12   
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(E2F3b-5) and inhibitory E2Fs (E2F6-E2F8). The expression of activator E2Fs varies during the cell 
cycle reaching a peak of activity, bound to target gene promoters via E2F response elements, during 
late G1/S phase. In this context, they control the expression of genes and activities required for DNA 
synthesis [53,67,68]. The expression and activity of the repressor E2Fs (E2F3b, E2F4, E2F5, E2F6) 
remain relatively constant throughout the cell cycle [53]. They bind target gene promoters during G0 
with E2F inhibitory pocket proteins coupled with repressive histone deacetylases [39,69] and prevent 
promiscuous transcription of proliferation genes [53,57,70]. The so-called repressor E2Fs get their 
name due to their ability to actively recruit transcriptional inhibitors such as histone deacetylase 1 (e.g., 
E2F4  and  5)  or  PRC2  (E2F6)  to  the  E2F  sites  resulting  in  transcriptional  repression  [57,58].  
In contrast, inhibitory E2Fs (E2F 7 and 8) compete for binding sites with other E2Fs and mediate their 
inhibition by excluding active or repressive E2Fs from binding [55]. The expression of E2F7 and E2F8 
is cell-cycle regulated. Transcription of E2F7 and E2F8 increases towards G1-to-S transition reaching 
its  peak  during  S-to-G2 transition  [28,57,59,60,71].  Thus,  the  role  of  E2F7/8  in  cell  cycle  control 
appears to tie in with the direct inhibition of the E2F1 activities related to cell cycle traverse [42,63].  
In contrast, the role of the inhibitory E2Fs in the control of differentiation appears to be isoform-specific 
and is mediated via isoform-specific DNA response elements [26,54]. Finally, the anti-apoptotic action 
of the inhibitory E2Fs appears to be mediated via direct inhibition of E2F1-mediated apoptosis [42,63]. 
The  interplay  between  E2F1-stimulated  apoptosis  and  E2F7/8-mediated  inhibition  of  apoptosis  is 
critical to understanding the role of E2Fs in UV-induced skin cancer formation and their potential as 
drugable targets for treating squamous cell carcinomas or enhancing chemotherapeutic responses. 
6. E2F-Induced Apoptosis and Skin Cancer Formation 
The ability of the different E2Fs to contribute to apoptosis especially to UV-mediated apoptosis is 
contentious.  Much  of  this  controversy  arises  from  some  seemingly  paradoxical  data  relating  to  
the action of E2F1. Earlier studies with E2F1 reported that overexpression of E2F1 in tissue culture 
cells  and  in  transgenic  mice  caused  a  stimulation  of  apoptosis  and  an  enhancement  of  tumour 
formation [33,34,72,73]. In particular, overexpression of E2F1 in the epidermis of transgenic mice 
caused elevated apoptotic indices in keratinocytes of the basal layer and an increase in skin tumour 
formation in mice that overexpressed E2F1 and cyclin D1 [34]. In contrast, mice transgenic for E2F4 
expression  in  skin  did  not  have  increased  apoptotic  indices  [74].  Similarly,  mice  deficient  for  
E2F1  were  predisposed  to  thymomas  due  to  their  inability  to  delete  t  cells  via  E2F1-mediated 
apoptosis [75,76]. These earlier studies clearly supported the concept that the pro-proliferative actions 
of  E2F1  were  oncogenic  whilst  the  pro-apoptotic  actions  of  E2F1  were  tumour  suppressive  [77].  
E2F1-stimulated apoptosis can be mediated by p53-dependent and p53-independent pathways. The 
p53-dependent  pathway  involves  the  stabilization  of  p53  via  p14/p19
ARF  [78]  whilst  activation  of 
APAF1 and p73 or CHK2 is required for p53-independent apoptosis [79–81]. In response to UV, E2F1 
transcript and protein levels increase in an ATM/ATR dependent manner and leads to accumulation of 
events required for apoptosis [82]. This suggested that UV-induced E2F1 mediated apoptosis in skin 
may  have  tumour  suppressive  effects.  However,  studies  by  Dimova  and  Dyson  reported  that  the 
ectopic expression of E2F1 may result in the expression of survival genes suggesting that E2F1 may be 
anti-apoptotic under certain conditions [48]. This suggests that the role of E2F1 in regulating apoptosis Int. J. Mol. Sci. 2011, 12                       
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may  be  context-specific.  Consistent  with  this,  it  has  been  reported  that  E2F1  is  anti-apoptotic  in 
keratinocytes in the context of UVB irradiation [52,83]. Specifically, E2F1 deficient mice and mice 
transgenic for E2F1 in skin displayed increased and reduced apoptotic indices in response to UVB 
irradiation respectively [52,78]. Wikonkal et al. [52] also showed that the pro-survival effect of E2F1, 
in response to UVB, was p53-independent. Finally, it was shown that the pro-survival effect of E2F1, 
in response to UVB irradiation of keratinocytes/epidermis could be attributed to the ability of E2F1 to 
sense  DNA  damage  and  co-ordinate  the  DNA  damage  repair  [52].  In  this  regard,  E2F1  has  been 
reported  to  function  directly  at  sites  of  DNA  repair  to  eliminate  DNA  photoproducts  [84,85]  or 
indirectly by controlling the transcription of genes required for DNA repair machinery [86,87].  
Whilst these data appear to definitively show that E2F1 is oncogenic in skin due to its anti-apoptotic 
effects, there still remain some unresolved issues. For example, studies have shown that E2F1-mediated 
responses to UVB irradiation may be dose-dependent such that low doses of UVB activate DNA repair 
mechanisms whilst high doses induce apoptosis in cells in which the cellular DNA repair machinery is 
unable to repair the damage [88]. Moreover, another important consideration is the level of E2F1. For 
example,  it  is  easy  to  see  the  benefit  of  a  pro-survival  signal  being  generated  in  response  to  the 
relatively low levels of E2F1 that may be experienced during cell cycle traverse. It is also easy to see 
biological justification that elevation of E2F1, in response to stressors such as UVB, could invoke 
apoptotic responses [89,90]. Earlier studies by Yang and his colleagues have shown that E2F6 is able 
to  repress  UV-induced  apoptosis  in  human  embryonic  kidney  cells  via  direct  interaction  with  
BRCA1  [91].  Intriguingly,  the  expression  of  E2F6  is  influenced  by  E2F1  [92].  However,  it  is 
noteworthy that keratinocytes do not appear to express detectable levels of E2F6 [51] suggesting this 
situation may not apply in skin. The same cannot be said for recent studies with E2F7 and E2F8. E2F7 
and  8  are  inhibitory  E2Fs  that  bind  to,  and  repress,  E2F1  transcription  and  E2F1-induced  
apoptosis [63]. Both E2F7 and E2F8 are expressed in skin [57,61] and are able to influence the cellular 
DNA damage response [41]. Zalmas et al. [41] demonstrated that DNA damage induced by etoposide 
treatment  induced  E2F7  and  E2F8  expression.  Moreover,  they  demonstrated  that  DNA  damage 
invoked an increase in E2F7 and E2F8 binding to E2F-responsive genes such as E2F1 resulting in an 
inhibition of E2F1-mediated apoptosis [41]. In fact, microarray analysis of cells subjected to DNA 
damage  revealed  that  E2F7  and  E2F8  could  be  considered  bona  fide  DNA  damage  response  
genes [58,63] (Figure 3). These studies seem to be relevant to skin UV responses since we recently 
reported that E2F7 plays a role in regulating proliferation, differentiation and UV-induced cytotoxicity 
in human keratinocytes in vitro [26]. Moreover, we reported that E2F1 and E2F7 were overexpressed 
in  human  squamous  cell  carcinomas  approximately  50  fold  and  200  fold  respectively  [26].  Such 
elevations in E2F1 and E2F7 are clearly pathologic and the consequences on UV-induced tumour 
development  and  progression  remain  unknown.  However,  given  that  E2F1  and  E2F7  are  said  to 
autoregulate the expression of one another and given that E2F7 antagonises E2F1-induced apoptosis 
and UV-induced apoptosis in human keratinocytes [26], it would seem reasonable to speculate that 
E2F7 may also play a role in UV responses in human epidermis (Figure 4). Thus, apoptotic responses 
of keratinocytes, to UV, or chemotherapeutics, are likely to be dictated by the relative levels of E2F1 
and E2F7. 
   Int. J. Mol. Sci. 2011, 12   
 
Figure 3. Regulatory network on 
(growth-dependant and/or DNA
Figure 4. Schematic showing how 
malignancies due to dysregulated apoptotic control.
            
Regulatory network on E2F1 and E2F7/8 activity representing upstream events 
dependant and/or DNA damage mediated activation) and downstream targets.
showing how E2F1 and E2F7 contribute to formation of cutaneous 
dysregulated apoptotic control.  
      
 
8954 
7/8 activity representing upstream events 
damage mediated activation) and downstream targets. 
  
7 contribute to formation of cutaneous 
  Int. J. Mol. Sci. 2011, 12                       
 
 
8955 
In conclusion, the carcinogenic components of sunlight, relevant to humans, are UVA and UVB. 
UV radiation induces either a cell cycle arrest or an apoptotic response in human keratinocytes. Both 
the cell cycle arrest and the apoptotic response appear to be mediated by E2F1. More recently, an 
antagonistic form of E2F, E2F7, has been reported that antagonizes the pro-proliferative and apoptotic 
effects of E2F1. Both E2F1 and E2F7 are significantly overexpressed in transformed keratinocytes and 
there is evidence that the dysregulation of expression of the E2F1 and E2F7 isoforms may contribute 
to skin cancer formation. 
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